← All trials
NCT05486195
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2019
- Primary completion
- Jul 29, 2019
- Completion date
- Mar 11, 2020
- First posted
- Aug 3, 2022
- Last posted
- Aug 3, 2022
- Enrollment
- 32
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AbbVieLead sponsor
- Katholieke Universiteit LeuvenCollaborator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- SyndesiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.